Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.
Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S, Pritchard K, Eisen A, Vandenberg T, Taylor M, Sauerbrei E, Mishaeli M, Huntsman D, Walsh W, Olivo M, McIntosh L, Seymour L. Ellard SL, et al. Among authors: vandenberg t. J Clin Oncol. 2009 Sep 20;27(27):4536-41. doi: 10.1200/JCO.2008.21.3033. Epub 2009 Aug 17. J Clin Oncol. 2009. PMID: 19687332 Clinical Trial.
A phase II study of ZD0473 given as a short infusion every 3 weeks to patients with advanced or metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group trial, IND 129.
Gelmon KA, Vandenberg TA, Panasci L, Norris B, Crump M, Douglas L, Walsh W, Matthews SJ, Seymour LK. Gelmon KA, et al. Among authors: vandenberg ta. Ann Oncol. 2003 Apr;14(4):543-8. doi: 10.1093/annonc/mdg171. Ann Oncol. 2003. PMID: 12649098 Free article. Clinical Trial.
Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.
Pritchard KI, Shepherd LE, Chapman JA, Norris BD, Cantin J, Goss PE, Dent SF, Walde D, Vandenberg TA, Findlay B, O'Reilly SE, Wilson CF, Han L, Piura E, Whelan TJ, Pollak MN. Pritchard KI, et al. J Clin Oncol. 2011 Oct 10;29(29):3869-76. doi: 10.1200/JCO.2010.33.7006. Epub 2011 Sep 12. J Clin Oncol. 2011. PMID: 21911723 Clinical Trial.
A Phase 2 study of perifosine in advanced or metastatic breast cancer.
Leighl NB, Dent S, Clemons M, Vandenberg TA, Tozer R, Warr DG, Crump RM, Hedley D, Pond GR, Dancey JE, Moore MJ. Leighl NB, et al. Breast Cancer Res Treat. 2008 Mar;108(1):87-92. doi: 10.1007/s10549-007-9584-x. Epub 2007 Apr 26. Breast Cancer Res Treat. 2008. PMID: 17458693 Clinical Trial.
Phase II trial of N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine.HCl and doxorubicin chemotherapy in metastatic breast cancer: A National Cancer Institute of Canada clinical trials group study.
Khoo K, Brandes L, Reyno L, Arnold A, Dent S, Vandenberg T, Lebwohl D, Fisher B, Eisenhauer E. Khoo K, et al. Among authors: vandenberg t. J Clin Oncol. 1999 Nov;17(11):3431-7. doi: 10.1200/JCO.1999.17.11.3431. J Clin Oncol. 1999. PMID: 10550138 Clinical Trial.
Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer.
Burnell M, Levine MN, Chapman JA, Bramwell V, Gelmon K, Walley B, Vandenberg T, Chalchal H, Albain KS, Perez EA, Rugo H, Pritchard K, O'Brien P, Shepherd LE. Burnell M, et al. Among authors: vandenberg t. J Clin Oncol. 2010 Jan 1;28(1):77-82. doi: 10.1200/JCO.2009.22.1077. Epub 2009 Nov 9. J Clin Oncol. 2010. PMID: 19901117 Free PMC article. Clinical Trial.
73 results